Molecular pharmacology of somatostatin receptor subtypes.
about
Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cellsFrom targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsClinical utility of lanreotide AutogelĀ® in gastroenteropancreatic neuroendocrine tumorsSynthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2Processing of rat preprocortistatin in mouse AtT-20 cells.Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.Somatostatin analogs and radiopeptides in cancer therapy.Mechanism and its regulation of tumor-induced angiogenesis.Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomasPET in the diagnosis of neuroendocrine tumors.Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Identification of critical residues involved in ligand binding and G protein signaling in human somatostatin receptor subtype 2.A Transcriptome-Led Exploration of Molecular Mechanisms Regulating Somatostatin-Producing D-Cells in the Gastric Epithelium.Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumorsInhibitory effect of octreotide on gastric cancer growth via MAPK pathway.Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation.Somatostatinoma: clinico-pathological features of three cases and literature reviewed.Involvement of somatostatin receptor subtypes in membrane ion channel modification by somatostatin in pituitary somatotropes.Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation.Use of somatostatin analogues in obesity.Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.Investigation of responsiveness to thyrotropin-releasing hormone in growth hormone-producing pituitary adenomas.The beta-D-glucose scaffold as a beta-turn mimetic.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs).Cross-talk and modulation of signaling between somatostatin and growth factor receptors.Translation of molecular pathways into clinical trials of neuroendocrine tumors.Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectivesNovel gold nanoparticles coated with somatostatin as a potential delivery system for targeting somatostatin receptors.Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.Somatostatin decreases voltage-gated Ca2+ currents in GH3 cells through activation of somatostatin receptor 2.Treatment of neuroendocrine tumors with somatostatin analogs.Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors.Signal transduction of somatostatin in human B lymphoblasts.Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study.SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release.Activation of Muscarinic Acetylcholine Receptor Subtype 4 Is Essential for Cholinergic Stimulation of Gastric Acid Secretion: Relation to D Cell/Somatostatin.Syntheses and biological activities of sandostatin analogs containing stereochemical changes in positions 6 or 8.
P2860
Q24681476-AF4FBBD8-7AE0-4DF4-BFF5-9DCE9FCE9A79Q24812181-513F0790-A4F5-4F56-B630-2804F8410F2EQ26822011-FB178E96-4B33-483D-8EA4-81C2A1EB783DQ28069632-BCE58978-9D71-416E-BC42-1748B549C2A1Q28368778-0EE245E2-3E01-4003-BCFC-6274B0B00212Q33872112-225480BA-CAD4-4998-AE64-850FFF257992Q34117185-9F26BCE7-3940-4CB9-AA13-A877A59749F4Q34972896-582B8920-9F31-492B-A280-0F6EF7511887Q35151099-CE41703C-64DA-4E36-951A-A64A038A45FDQ35769837-B951499A-725C-4489-8463-6BE398752484Q35778295-76C2D7F2-E7B8-4883-ACB9-E56A9F71E00EQ35891113-768D5E32-9194-421D-ADCE-DE13C02DA25AQ35986032-8000C37A-9331-4872-8BCD-F007DE3FBA56Q36164350-FDEA4F1C-1395-40C6-BDDF-ED507F371048Q36270932-0087C7BF-6261-4E70-A117-CB3C8C850966Q36309149-3BDBF35F-847F-4E80-BCC4-C10AB8C28095Q36610457-8EFA6E23-0CF1-4958-8876-4080152EED19Q36889060-8DCD9EA9-0F09-4310-94B0-940D31AC84FBQ36950543-0C9B576B-89C8-4813-B787-ACCCE7C43BE3Q37107084-AE7F3AA0-BB6F-4BB8-8389-ADB37132A392Q37263193-795E8620-393A-4514-B3E6-8C3BDAB1B38BQ37365221-778E1F0B-0C5F-4D1F-8B7A-CC8E199ABBEAQ37379903-03B67F0A-E883-4B6A-906A-2F61F71FB177Q37394232-EEF3B64F-6311-4A8E-B4CF-3B5537B78C44Q37579225-365911EC-B523-4259-8031-CAAF8F529C00Q37771118-15B99775-C44D-4831-81A5-C2A5170848C8Q37922648-658BB134-BCC6-497E-8614-4E8D76EF7FA2Q38003074-2BAD4BD1-12C7-4DD0-BE22-577CC8A198C7Q38216009-83F4D80F-FA30-487B-BDED-E577EBEB972FQ38782137-3BD2157B-F192-4D50-A363-287248E160D9Q38990078-F4D5C3D5-D8B0-4468-AA65-84646BFA94AAQ40165727-2A181C14-10CB-4260-A43F-2F928A2D913BQ40284987-FB4F351C-9FE3-44BC-B2BC-5C630B4B8A86Q40469120-B5E2540C-EDF0-4E96-9ED9-EB68CC0FE45CQ40505318-4EE24632-9689-41EA-9FB0-E5C5B7B35016Q40696292-0B9311F6-F048-4707-AE4C-1BBCBD699DDEQ40835915-24602693-3058-45C9-AE23-0BB32A49CC11Q40933861-A01FC493-3660-4D41-B498-000CEBB95D37Q40969450-83AD926E-3302-49D3-AA4C-AA9C080B4186Q41731395-E7FD6208-55BE-4A6B-A11C-BB09633FF09C
P2860
Molecular pharmacology of somatostatin receptor subtypes.
description
1997 nĆ® lÅ«n-bĆ»n
@nan
1997幓ć®č«ę
@ja
1997幓č«ę
@yue
1997幓č«ę
@zh-hant
1997幓č«ę
@zh-hk
1997幓č«ę
@zh-mo
1997幓č«ę
@zh-tw
1997幓č®ŗę
@wuu
1997幓č®ŗę
@zh
1997幓č®ŗę
@zh-cn
name
Molecular pharmacology of somatostatin receptor subtypes.
@en
type
label
Molecular pharmacology of somatostatin receptor subtypes.
@en
prefLabel
Molecular pharmacology of somatostatin receptor subtypes.
@en
P2860
P356
P1476
Molecular pharmacology of somatostatin receptor subtypes.
@en
P2093
P2860
P2888
P304
P356
10.1007/BF03350317
P577
1997-06-01T00:00:00Z
P6179
1053644664